Compare TPR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPR | UTHR |
|---|---|---|
| Founded | 1941 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 23.9B |
| IPO Year | 2000 | 1999 |
| Metric | TPR | UTHR |
|---|---|---|
| Price | $120.83 | $553.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 15 |
| Target Price | $163.55 | ★ $687.14 |
| AVG Volume (30 Days) | ★ 2.3M | 424.2K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ 786.59 | 13.07 |
| EPS | 1.76 | ★ 18.80 |
| Revenue | ★ $5,880,000,000.00 | $1,483,300,000.00 |
| Revenue This Year | $7.48 | $2.15 |
| Revenue Next Year | $5.17 | $11.39 |
| P/E Ratio | $70.27 | ★ $29.74 |
| Revenue Growth | ★ 31.01 | 2.38 |
| 52 Week Low | $104.50 | $455.63 |
| 52 Week High | $164.80 | $614.23 |
| Indicator | TPR | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 41.91 |
| Support Level | $110.81 | $525.83 |
| Resistance Level | $120.88 | $584.47 |
| Average True Range (ATR) | 4.64 | 19.66 |
| MACD | -1.01 | -5.98 |
| Stochastic Oscillator | 5.51 | 4.97 |
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 86% of its revenue and all its operating profit in fiscal 2026. Coach was founded as a leathergoods company in 1941, and handbags represented 58% of its fiscal 2026 revenue. Coach products are sold through nearly 1,000 company-owned stores, company-operated digital channels, and wholesale partners in North America, Asia, and Europe. Tapestry also owns Kate Spade (13% of fiscal 2026 revenue), which operates more than 300 worldwide stores and generated 55% of its revenue from handbags in fiscal 2025. Founded in 1993, Kate Spade is known for its colorful patterns and graphics.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.